Devyser Diagnostics AB (publ) Interim report January-June 2024



Continued strong sales growth

Quarter from April to June 2024

- Net sales amounted to SEK 53.2 million (37.7), corresponding to a 41.1 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 40.1 percent.
- Gross profit totaled SEK 41.4 million (31.5), corresponding to a gross margin of 77.7 percent (83.4).
- Operating profit (EBIT) amounted to SEK -23.1 million (-13.5).
- Profit after tax totaled SEK -22.9 million (-14.6).
- Earnings per share before and after dilution amounted to SEK -1.41 (-0.90).
- Cash flow from operating activities stood at SEK -15.9 million (-22.8).

Important events during the quarter

IVDR approval for post-transplant monitoring software Devyser was granted IVDR approval for its Advyser Solid Organs software, which is used with the One Lambda Devyser Accept cfDNA product (for monitoring in connection with kidney transplantation). This is Devyser's first software to be given IVDR approval under the new, more comprehensive regulation that came into force in May 2022.

Devyser won a record-breaking tender in Italy

In June, Devyser was awarded a five-year extension agreement with the Tuscany region of Italy for ten of its products. Devyser was also awarded the transplant part of the tender through its distribution partner. The estimated order value for Devyser is approximately SEK 12 to 15 million annually, out of which around half is new revenue and half is a renewal of current contracts.

Devyser expanded its commercial collaboration with Thermo Fisher Scientific

In June, Devyser expanded the exclusive collaboration and distribution agreement with Thermo Fisher Scientific. The agreement gives Thermo Fisher exclusive rights to market Devyser's NGS products for posttransplant monitoring worldwide under combined trademarks. This is an extension of the previously announced agreement whereby Thermo Fisher had exclusive rights to market these products in North America, Europe, Brazil and Saudi Arabia.

The period from January to June 2024

- Net sales amounted to SEK 104.0 million (77.2), corresponding to a 34.6 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 33.5 percent.
- Gross profit totaled SEK 83.3 million (65.1), corresponding to a gross margin of 80.1 percent (84.3).
- Operating profit (EBIT) amounted to SEK -35.3 million (-32.6).
- Profit after tax totaled SEK -35.1 million (-34.5).
- Earnings per share before and after dilution amounted to SEK -2.15 (-2.14).
- Cash flow from operating activities stood at SEK -32.5 million (-42.1).

Annual General Meeting

At the Annual General Meeting in May, Mia Arnhult, Lars Höckenström, Fredrik Dahl and Pia Gideon were re-elected as Board members. Thomas Eklund was elected as a new member of the Board. Mia Arnhult was re-elected as Chair of the Board.

The share and new issues

Three new share issues were carried out during the quarter in connection with the exercising of warrants and employee stock options. The issues raised SEK 17.4 million for the company. The Annual General Meeting in May decided to introduce a new employee stock option program. See Note 2 on page 15.

Important events after the end of the quarter

Changes in the management team

COO Göran Rydin has announced his intention to leave Devyser during the fall. This means that the management team now consists of Fredrik Alpsten, CEO, Sabina Berlin, CFO, Theis Kipling, CCO and Head of Business Development, Michael Uhlin, CSO, and Camilla Wiberg, CHRO.

Important events during the period from January to June 2024

IVD development agreement with Illumina Inc.

In early January, a contract was signed with Illumina for IVD (in vitro diagnostics) development. This was to enable US and European regulatory registrations of Devyser's NGS tests on MiSeqDx, Illumina's FDA-regulated and CE-IVD-marked sequencing instrument.

Devyser Genomic Laboratories signed its first commercial contract

Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, signed its first commercial contract in mid-January with UKbased diagnostics company Cyted. The contract's term is initially two years, and revenues are estimated to total approximately SEK 25.0 million, of which up to around SEK 6.0 million in 2024.

IVDR approval for post-transplant monitoring software Devyser was granted IVDR approval for its Advyser Solid Organs software, which is used with the One Lambda Devyser Accept cfDNA product. This is Devyser's first software to be given IVDR approval under the new, more comprehensive regulation that came into force in May 2022.

Devyser won a record-breaking tender in Italy

In June, Devyser was awarded a five-year extension agreement with the Tuscany region of Italy for ten of its products. Devyser was also awarded the transplant part of the tender through its distribution partner. The estimated order value for Devyser is approximately SEK 12 to 15 million annually.

Devyser expanded its commercial collaboration with Thermo Fisher Scientific

In June, Devyser expanded the exclusive collaboration and distribution agreement with Thermo Fisher Scientific. The agreement gives Thermo Fisher exclusive rights to market Devyser's NGS products for posttransplant monitoring worldwide under combined trademarks. This is an extension of the previously announced agreement whereby Thermo Fisher had exclusive rights to market these products in North America, Europe, Brazil and Saudi Arabia.

The Board and management

The management team was expanded in February when it was joined by CSO Michael Uhlin. The latter has extensive experience in the global life sciences sector and has long been engaged in translational research and development.COO Göran Rydin has announced his intention to leave Devyser during the fall. This means that the management team now consists of Fredrik Alpsten, CEO, Sabina Berlin, CFO, Theis Kipling, CCO and Head of Business Development, Michael Uhlin, CSO, and Camilla Wiberg, CHRO.

At the Annual General Meeting in May, Mia Arnhult, Lars Höckenström, Fredrik Dahl and Pia Gideon were re-elected as Board members. Thomas Eklund was elected as a new member of the Board. Mia Arnhult was re-elected as Chair of the Board.

The share and new issues

Three new share issues were carried out during the period from January to June in connection with the exercising of warrants and employee stock options. The issues raised SEK 17.4 million for the company. The Annual General Meeting in May decided to introduce a new employee stock option plan. See Note 2 on page 15.

Performance measures	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jul 2023 - Jun 2024	Jul 2022 - Jun 2023
Net sales, SEK million	53.2	37.7	104.0	77.2	196.0	142.6
Sales growth, %	41.1	22.3	34.6	26.1	37.5	29.5
Gross margin, %	77.7	83.4	80.1	84.3	83.1	83.2
EBITDA, SEK million	-16.3	-11.1	-21.9	-27.5	-40.2	-56.7
EBITDA margin, %	Neg	Neg	Neg	Neg	Neg	Neg
Operating profit/loss (EBIT), SEK million	-23.1	-13.5	-35.3	-32.6	-61.6	-66.7
Operating margin (EBIT margin), %	Neg	Neg	Neg	Neg	Neg	Neg
Profit/loss after tax, SEK million	-22.9	-14.6	-35.1	-34.5	-54.2	-60.0
Cash flow from operating activities, SEK million	-15.9	-22.8	-32.5	-42.1	-60.1	-67.3
Cash and cash equivalents, SEK million	201.0	303.0	201.0	303.0	201.0	303.0
Net cash (-)/Net debt (+), SEK million	-136.1	-229.6	-136.1	-229.6	-136.1	-229.6
Equity ratio, %	75.1	75.9	75.1	75.9	75.1	75.9
Return on equity, %	Neg	Neg	Neg	Neg	Neg	Neg
Average no. of employees	120	98	119	96	113	89

See page 17 for definitions of the performance measures.

A word from the CEO

Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK and 40 percent in local currencies. We won several large tenders during the quarter, which are expected to start generating revenue in the second half of 2024. An expanded collaboration with Thermo Fisher in countries outside North America, Europe, Brazil and Saudi Arabia is also expected to increase sales starting from 2025.

Sales and results

Organic sales growth in the second quarter amounted to 41 percent in SEK and 40 percent in local currencies. For the first half of the year as a whole, sales growth came in at 35 percent in SEK and 34 percent in local currencies. Although these are high growth figures, we believe there is a strong prospect of growth being maintained, or even increased, over time. Among other things, we see continued potential in several direct markets in Europe where growth has been lower than expected in 2024. Our own sales in North America are still at an early stage, in terms of both the service offering from our CLIA lab and product sales. However, we have invested a lot in North America why we expect the sales to gain significant momentum within the next year. Sales of our transplant products to Thermo Fisher were good during the first half of the year, and are expected to pick up further in the second half.

Encouragingly, distributor sales in Asia, which were weak in the first quarter, gathered pace in the second quarter, growing by 75 percent. Over the past 12 to 18 months we have signed a number of distributor agreements in Asia and we are hopeful that these will now start to generate revenue.

Sales in South and North America are developing according to plan, with growth of 70 percent for the first half of the year, and 166 percent for the last 12 months.

Most of our nearly 30 products are developing well in terms of sales. The ones that are growing the most are our transplant products as well as our tests for thalassemia, cystic fibrosis and RHD.

The gross margin amounted to 78 percent, compared with 83 percent for the same quarter of last year. The lower gross margin is the result of increased costs, as our manufacturing is moved to new premises in 2024. The third quarter will also be affected. We estimate that we will be back to gross margins of more than 80 percent from the end of 2024.

We remain positive about the gross margin trend over time, partly because we have a scalable manufacturing process, with the move to new premises gradually facilitating the streamlining and automation of the production processes, and partly because we believe that we will still be able to continuously raise prices.

The results for the quarter were in line with expectations. The operating loss amounted to SEK -23 million, compared with SEK -14 million for the same quarter of last year. The lower result is due to the cost of moving to new premises, double rents and the increased cost of our expansion in North America.

The rise in Devyser's share price also meant that we were hit with higher costs for our incentive program plans. The total cost resulting from the rise in the price of the Devyser share amounted to SEK 2 million during the quarter.

"Although these are high growth figures, we believe there is a strong prospect of growth being maintained, or even increased, over time."

Expanded collaboration with Thermo Fisher Scientific

Sales to Thermo Fisher developed well during the first two quarters, and are expected to pick up further during the rest of the year. During the quarter, we further strengthened our collaboration through a new agreement that gives Thermo Fisher global distribution rights for the products, which we believe will significantly facilitate the rapid and cost-effective ramp-up of sales of our transplant products outside North America, Europe, Brazil and Saudi Arabia. The expanded collaboration increases the addressable market for current transplant products by almost 50 percent. The new countries are expected to start generating sales from 2025 onwards.

Strong future prospects

DNA diagnostics is central in healthcare for diagnosis and treatment planning. The strong growth in genetic testing is driven by global macro trends such as population growth and improved standard of living. Prevention, screening programs and increased awareness of genetic testing is also contributing to the growth, justified by both financial and healthcare-related incentives.

Given the considerable investments made in both Europe and the US, and the expected increase in sales to Thermo Fisher and through our CLIA lab, we remain convinced that the positive sales and earnings trends that we saw in 2023 will continue, and that we will achieve our financial target of an operating margin of more than 20 percent during the 2024-2026 period.

All in all, the second quarter of 2024, like the first quarter of 2024, has been a very eventful quarter and I am looking ahead to the rest of the year with confidence.

Stockholm, July 22, 2024

Fredrik Alpsten, CEO



Group development, January-June 2024

Net sales

Net sales for the period from January to June 2024 amounted to SEK 104.0 million (77.2), corresponding to a 34.6 percent increase. Adjusted for exchange rate fluctuations, the increase was 33.5 percent. The increase was driven by higher direct sales and distributor sales.

Net sales for the second quarter of 2024 amounted to SEK 53.2 million (37.7), corresponding to a 41.1 percent increase. Adjusted for exchange rate fluctuations, the increase was 40.1 percent.

There are no major seasonal variations in the company's sales.

Gross profit

Gross profit for the period from January to June 2024 totaled SEK 83.3 million (65.1). Gross profit for the second quarter totaled SEK 41.4 million (31.5).

The gross margin for the period from January to June 2024 amounted to 80.1 percent, compared with 84.3 percent for the same period of the previous year. For the second quarter, the gross margin amounted to 77.7 percent, compared with 83.4 percent for the same quarter of last year. The lower gross margin is mainly attributable to moving costs in connection with the relocating of the business to new premises.

The cost of goods sold includes the direct costs of producing the products sold, the amortization of capitalized development expenses, the overhead expenses for the production department, and personnel expenses for the department's employees.

The amortization of capitalized development expenses amounted to SEK 2.4 million (0.8) for the period from January to June 2024, and SEK 1.2 million (0.3) during the second quarter of 2024.

Operating expenses

Operating expenses for the period from January to June 2024 came to SEK 121.4 million (100.0), and for the second quarter to SEK 63.5 million (47.2). The increase in expenses is primarily due to the recruitment of sales, development and administrative personnel as part of the company's growth strategy, expenses relating to the implementation of a new ERP system and CRM system, the cost of two rents (for the old and new premises) and incentive program costs.

Total research and development expenses during the period from January to June 2024 amounted to SEK 36.1 million (28.0), of which SEK 11.3 million (10.5) were capitalized and SEK 24.7 million (17.5) were expensed. During the second quarter of 2024, research and development expenses totaled SEK 19.1 million (13.7), of which SEK 5.1 million (7.3) were capitalized and SEK 14.0 million (6.4) were expensed.

The expensed research and development costs mainly comprise employee and consultant-related costs attributable to the R&D department's non-capitalizable project phases. The capitalized expenses include costs for development projects related to products not yet completed.

During the period from January to June 2024, other operating income and expenses, primarily exchange rate differences on current assets and short-term liabilities, came to a net amount of SEK 2.8 million (2.2), and SEK -0.9 million (2.2) for the second quarter.

Operating profit/loss


Operating profit for the period from January to June 2024 totaled SEK -35.3 million (-32.6). For the second quarter, operating profit stood at SEK -23.1 million (-13.5). The reason for the negative operating result for both 2024 and 2023 is primarily increased investments in sales in the form of new hires.

Net financial items

Net financial items for the period from January to June 2024 totaled SEK 1.8 million (-0.4). For the second quarter, net financial items stood at SEK 0.5 million (-0.2).

Profit/loss

Profit before tax for the period from January to June 2024 was SEK -33.5 million (-33.0), and profit after tax was SEK -35.1 million (-34.5). For the second quarter, profit before tax was SEK -22.6 million (-13.8), and after tax was SEK -22.9 million (-14.6). See Note 7 on page 16.



Sales by region, SEK million	Apr - Jun 2024	Apr - Jun 2023	Change, %	Jan - Jun 2024	Jan - Jun 2023	Change, %	Jul 2023 - Jun 2024	Jul 2022 - Jun 2023	Change, %
EMEA	47.6	33.0	44.3	92.8	69.9	32.7	172.3	130.8	31.7
Asia- Pacific	2.4	1.4	74.5	3.5	2.7	26.7	6.8	5.4	25.5
North and South									
America	3.3	3.4	-3.7	7.7	4.6	69.9	16.9	6.4	166.4
Total	53.2	37.7	41.1	104.0	77.2	34.6	196.0	142.6	37.5

Sales by sales channel, SEK million	Apr - Jun 2024	Apr - Jun 2023	Change, %	Jan - Jun 2024	Jan - Jun 2023	Change, %	Jul 2023 - Jun 2024	Jul 2022 - Jun 2023	Change, %
Direct sales	39.6	29.2	35.6	77.9	62.1	25.5	146.7	114.3	28.2
Distributor									
sales	13.7	8.5	59.8	26.1	15.2	72.0	49.4	28.2	74.8
Total	53.2	37.7	41.1	104.0	77.2	34.6	196.0	142.6	37.5

Cash flow and cash position

For the period from January to June 2024, cash flow from operating activities after changes in working capital was SEK -32.5 million (-42.1). For the second quarter of 2024, cash flow from operating activities was SEK -15.9 million (-22.8). During the period, three new issues of 178,916 shares were completed in connection with the exercising of warrants and employee stock options issued to employees, which brought in SEK 17.4 million for the company. Cash and cash equivalents as of June 30, 2024 amounted to SEK 201.0 million (303.0).

Investments

Total net investments came to SEK 38.3 million (19.8), including capitalized development expenses of SEK 14.1 million (10.5) and SEK 19.2 million (0.0) related to the move to the new premises in Årsta and investments in increased manufacturing capacity. The Group has no investment commitments.

Assets

As of June 30, 2024, intangible non-current assets amounted to SEK 71.6 million (49.8). The intangible non-current assets consist of the capitalized development expenses for Devyser's products, license fees, capitalized development expenses for software and goodwill acquired from the subsidiary SmartSeq S.r.l., totaling SEK 6.7 million (7.0), and the subsidiary TrenDx AB, totaling SEK 0.2 million (0.2). Capitalized development expenses are amortized on a straight-line basis over their estimated useful lives. which varv from five to ten vears.

The amortization of capitalized development expenses attributable to the products developed by Devyser is recognized in the Group cost of goods sold and in the Parent Company's research and development costs.

During the period, Devyser began its move to new premises in Årsta in Stockholm. The lease was signed during the second quarter of 2023 and will run for seven years, with a four-year option. The asset's value is recognized in Right-of-use assets, and the related liability in Lease liabilities. The value of the total right-of-use assets as of June 30, 2024 was SEK 66.9 million (73.0).

Equity and liabilities

As of June 30, 2024, the Group's equity amounted to SEK 367.9 million (400.3), and its equity ratio was 75.1 percent (75.9).

As of June 30, 2024, interest-bearing liabilities amounted to SEK 64.8 million (73.4). Interest-bearing liabilities relate mainly to lease liabilities. Current non-interest-bearing liabilities totaled SEK 52.4 million (49.6).

Important events in the Parent Company

The improvement in the Parent Company's profit is mainly due to higher intra-Group revenues, mainly royalty revenue from the subsidiary Devyser AB. During the period, three new issues of 178,916 shares were completed in connection with the exercising of warrants and employee stock options issued to employees, which brought in SEK 17.4 million for the company.

Performance measures by quarter	Apr - Jun 2024	Jan - Mar 2024	Oct - Dec 2023	Jul - Sep 2023	Apr - Jun 2023	Jan - Mar 2023	Oct - Dec 2022
Net sales, SEK million	53.2	50.7	45.4	46.7	37.7	39.5	34.2
Gross profit, SEK million	41.4	41.9	40.0	39.6	31.5	33.7	27.2
Gross margin, %	77.7	82.7	88.1	85.0	83.4	85.2	79.5
EBITDA, SEK million	-16.3	-5.6	-14.2	-4.1	-11.1	-16.3	-23.4
EBITDA margin, %	Neg						
Operating profit/loss (EBIT), SEK million	-23.1	-12.2	-18.5	-7.8	-13.5	-19.1	-25.9
Operating margin (EBIT margin), %	Neg						
Profit/loss after tax, SEK million	-22.9	-12.2	-13.1	-6.0	-14.6	-19.9	-16.7
Cash flow from operating activities, SEK million	-15.9	-16.5	-13.8	-13.9	-22.8	-19.3	-13.4
Average no. of employees	120	119	111	102	98	93	87

See page 17 for definitions of the performance measures.

Parent Company

Devyser Diagnostics AB (publ), Corporate Registration Number 556669-7834, is a Swedish limited company domiciled in Stockholm. The address of its head office is Instrumentvägen 19, 126 53 Hägersten, Sweden. Devyser Diagnostics AB has been listed on the Nasdag First North Premier Growth Market since December 2021.

Receivables and liabilities in respect of Group companies primarily consist of amounts owed by the Swedish subsidiary Devyser AB and the Italian subsidiary Devyser Italia S.r.I. The Parent Company's risks and uncertainties indirectly coincide with those of the Group.

Employees

From January to June 2024, the average number of Group employees was 119 (96), of which 2 (2) in the Parent Company. The average number broken down by country was 86 (68) in Sweden, 17 (13) in Italy, 8 (6) in the United States, 3 (3) in Germany, 2 (2) in Belgium, 1 (1) in the United Kingdom, 1 (1) in Spain and 1 (1) in France. The average number of women employed by the Group was 73 (56) and the average number of men was 46 (40). At the balance sheet date, the number of employees was 127 (106).

Market

Devyser sells genetic testing products to laboratories in more than 65 countries. The products include reagent kits and the related software. Sales are made primarily to routine diagnostic laboratories, partly through our own sales teams in selected markets and partly through distributors.

The products are used for complex DNA testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

The market size for the company's products is large and, according to an external market survey conducted in 2021, should reach EUR 5.6 billion by 2026.

Related-party transactions

See Notes 2 and 3 on page 15 for a description of the related-party transactions.

Significant risks and uncertainties

The Group's activities are associated with a number of risks and uncertainties.

Russia's invasion of Ukraine and the war in Gaza have no direct impact on Devyser, as it has no or limited business activities in the countries concerned.

The current market turmoil and inflation, and changes in interest rates, may have an impact on the industry, and on Devyser's operating expenses and sales growth. A possible recession could negatively affect future revenues. Devyser's sales are mainly in Euros and US dollars, meaning that the company is exposed to exchange rate fluctuations.

For more information, a detailed description of the company's risk exposure can be found in the 2023 Annual Report, pages 41-42, and in Note 15, pages 79-87. No changes are considered to have occurred since the Annual Report was published other than those described above.

The share and shareholders

As of June 30, 2024, Devyser Diagnostics AB had a total of 16,463,385 (16,161,169) shares and votes.

On the submission date of this report, the company had four

outstanding incentive programs for employees and key personnel. The new and existing incentive programs may currently increase the number of shares by 895,833 (see Note 2 on page 15).

The largest shareholders as of June 30, 2024 were:

	Number of	Ownership,
Owner	shares	% when ship,
Rutger Arnhult via company	4,035,000	24.5
Nordnet Pensionsförsäkringar	1,957,643	11.9
Swedbank Robur	1,304,100	7.9
Fourth Swedish National Pension Fund	759,821	4.6
Åsa Riisberg via company	664,294	4.0
Ferd	640,603	3.9
Berenberg Asset Management on behalf of Universal Investment funds	628,746	3.8
Deka Investments	420,200	2.6
Anders Hedrum, privately and via		
company	405,100	2.5
Insr Insurance Group	381,973	2.3
Other shareholders, around 900	5,265,905	32.0
Total	16,463,385	100.0

After the balance sheet date, a new share issue was made in

connection with the exercise of warrants, and at the time of submission of this report the number of shares is 16,484,335.

Analysts covering the Company

Ulrik Trattner, Carnegie Oscar Bergman, Redeye Johan Unnérus, Redeye

Auditors' review

This report has not been reviewed by the company's auditors.

The Board of Directors and CEO certify that the interim report provides a true and fair overview of the operations, financial position and earnings of the Group and the Parent Company and describes the significant risks and uncertainties faced by the Parent Company and the companies included in the Group.

Stockholm, July 22, 2024 Devyser Diagnostics AB (publ)

Mia Arnhult Chair of the Board

Thomas Eklund Board member Lars Höckenström Board member

Fredrik Alpsten CEO Fredrik Dahl Board member

Pia Gideon Board member

6

Consolidated statement of income and other comprehensive income

SEK million	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jan - Dec 2023
Net sales	53.2	37.7	104.0	77.2	169.3
Cost of goods sold	-11.9	-6.3	-20.7	-12.1	-24.5
Gross profit	41.4	31.5	83.3	65.1	144.7
Other operating income	2.9	4.7	6.8	5.9	9.0
Selling expenses ¹	-34.5	-30.7	-68.8	-61.5	-121.5
Administrative expenses	-15.0	-10.1	-27.9	-21.0	-42.0
Research and development costs	-14.0	-6.4	-24.7	-17.5	-37.8
Other operating expenses	-3.8	-2.5	-4.0	-3.7	-11.4
Operating profit/loss	-23.1	-13.5	-35.3	-32.6	-58.9
Financial income	1.4	0.0	3.6	0.0	5.3
Financial expenses	-0.9	-0.3	-1.8	-0.5	-0.8
Net financial items	0.5	-0.2	1.8	-0.4	4.5
Profit/loss before tax	-22.6	-13.8	-33.5	-33.0	-54.4
Tax ²	-0.4	-0.8	-1.6	-1.5	0.8
Profit/loss for the period	-22.9	-14.6	-35.1	-34.5	-53.6
Other comprehensive income					
Items which may be recognized in the income statement					
Exchange rate differences for the period when translating					
foreign subsidiaries	-0.5	1.1	0.0	1.5	0.3
Total other comprehensive income	-0.5	1.1	0.0	1.5	0.3
Total comprehensive income for the period	-23.4	-13.5	-35.1	-33.0	-53.2
Earnings per share before dilution, SEK	-1.41	-0.90	-2.15	-2.14	-3.31
Earnings per share after dilution, SEK	-1.41	-0.90	-2.15	-2.14	-3.31
Average no. of shares, before dilution	16,301,895	16,147,748	16,293,182	16,135,576	16,180,907
Average no. of shares, after dilution	17,197,727	17,155,786	17,189,014	17,143,614	17,052,245

Since there are no minority interests in the Group (no non-controlling interests), all earnings are wholly attributable to the owners of the Parent Company.

1) See Note 6 on page 16. 2) See Note 7 on page 16.

Consolidated statement of financial position

SEK million	June 30, 2024	June 30, 2023	Dec 31, 2023
ASSETS			
Non-current assets			
Goodwill	6.9	7.2	6.7
Capitalized development expenses	55.7	39.9	43.9
Other intangible assets	8.9	2.8	5.4
Equipment, tools and plant	35.1	17.2	17.1
Right-of-use assets	66.9	73.0	74.5
Deferred tax assets ²	20.9	18.5	20.6
Other non-current receivables	0.2	0.1	0.1
Total non-current assets	194.7	158.6	168.3
Current assets			
Inventories	26.3	14.8	20.6
Trade receivables	37.2	35.1	33.7
Current tax assets	2.3	0.7	1.9
Other receivables	9.7	5.5	9.7
Prepaid expenses and accrued income	18.6	9.6	13.0
Cash and cash equivalents	201.0	303.0	262.9
Total current assets	295.1	368.5	341.8
TOTAL ASSETS	489.8	527.1	510.1
EQUITY AND LIABILITIES			
EQUITY			
Share capital	0.9	0.9	0.9
Other paid-in capital	530.3	508.9	513.2
Translation reserve	1.2	2.3	1.2
Retained earnings, including profit/loss for the period	-164.5	-111.9	-130.2
TOTAL EQUITY	367.9	400.3	385.1
LIABILITIES			
Non-current liabilities			
Borrowings	0.4	0.5	0.6
Lease liabilities	49.7	66.8	56.7
Deferred tax liabilities	0.2	0.2	0.2
Provisions	1.2	0.9	1.0
Other non-current liabilities	3.3	2.6	3.7
Total non-current liabilities	54.7	71.0	62.1
Current liabilities			
Borrowings	0.1	0.1	-
Lease liabilities	14.6	5.9	17.5
Trade payables	15.0	12.6	14.2
Current tax liabilities	0.6	5.6	0.3
Other liabilities ¹	14.2	13.7	10.9
Accrued expenses and deferred income	22.6	17.8	20.0
Total current liabilities	67.1	55.7	62.9

1) See Note 6 on page 16.

2) See Note 7 on page 16.

Consolidated statement of changes in equity

SEK million	Share capital	Other paid- in capital	Translation reserve	Retained earnings, including profit/loss for the period	Total equity
Opening equity, Jan 1, 2023	0.9	507.6	0.8	-77.9	431.4
Comprehensive income					
Profit/loss for the period	-	-	-	-34.5	-34.5
Other comprehensive income for the period	-	-	1.5	-	1.5
Total comprehensive income	-		1.5	-34.5	-33.0
Shareholder transactions			1.0	01.0	
New share issues	0.0	1.4	-	-0.1	1.3
Warrants	-	-0.0	-	-	-0.0
Employee stock options	-	-	-	0.6	0.6
Closing equity, June 30, 2023	0.9	509.0	2.3	-112.0	400.3
Comprehensive income					
, Profit/loss for the period	-	-	-	-19.1	-19.1
Other comprehensive income for the period	-	-	-1.1	-	-1.1
Total comprehensive income	-	-	-1.1	-19.1	-20.2
Shareholder transactions					
New share issues	0.0	4.1	-	0.1	4.3
Warrants	-	0.0	-	-	0.0
Employee stock options	-	-	-	0.8	0.8
Closing equity, Dec 31, 2023	0.9	513.2	1.2	-130.2	385.1
Opening equity, Jan 1, 2024	0.9	513.2	1.2	-130.2	385.1
Comprehensive income					
Profit/loss for the period	-	-	-	-35.1	-35.1
Other comprehensive income for the period	-	-	0.0	-	0.0
Total comprehensive income	-	-	0.0	-35.1	-35.1
Shareholder transactions					
New share issues	0.0	17.4	-	-	17.4
New share issue expenses	-	-0.2	-	-	-0.2
Warrants	-	-0.0	-	-	-0.0
Employee stock options	-	-	-	0.8	0.8
Closing equity, Jun 30, 2024	0.9	530.3	1.2	-164.5	367.9

Consolidated cash flow statement

SEK million	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jan - Dec 2023
Cash flow from operating activities					
Operating profit/loss ¹	-23.1	-13.5	-35.3	-32.6	-58.9
Adjustment for non-cash items	20.1	10.0	00.0	52.0	50.7
- Depreciation, amortization and impairment	6.8	2.4	13.4	5.1	13.1
- Other non-cash items	1.0	0.3	2.1	0.7	2.0
Interest received	0.0	0.0	0.1	0.0	5.0
Interest paid	-0.9	-0.2	-1.8	-0.4	-0.8
Income tax paid	-0.6	-1.1	-0.5	0.7	-8.6
Cash flow from operating activities before changes in working	-16.8	-12.2	-22.0	-26.4	-48.2
capital	-10.8	-12.2	-22.0	-20.4	-40.2
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in inventories	-1.8	-4.1	-5.7	-4.6	-10.5
Increase (-)/Decrease (+) in operating receivables	-0.8	-3.1	-10.2	-10.3	-15.7
Increase (+)/Decrease (-) in operating payables	3.5	-3.4	5.4	-0.8	4.7
Cash flow from operating activities	-15.9	-22.8	-32.5	-42.1	-69.7
Cash flow from investing activities					
Investments in intangible non-current assets	-7.4	-7.4	-18.2	-10.9	-20.5
Investments in property, plant and equipment	-3.3	-5.6	-20.1	-8.9	-11.5
Cash flow from investing activities	-10.7	-13.0	-38.3	-19.8	-32.0
Cash flow from financing activities					
New share issues	16.6	0.7	17.4	1.3	5.6
New share issue expenses	-0.2	-	-0.2	_	-
Warrant programs	_	-0.0	-0.0	-0.0	-0.0
Repayments of borrowings	-0.1	-0.1	-0.1	-0.1	-0.1
Repayments of lease liabilities	-3.8	-0.8	-7.7	-1.9	-5.7
Cash flow from financing activities	12.5	-0.2	9.4	-0.6	-0.2
Cash flow for the period	-14.2	-36.0	-61.3	-62.5	-102.0
Cash and cash equivalents at the beginning of the period	215.0	337.4	262.9	363.6	363.6
Exchange gains/losses on cash and cash equivalents	0.1	1.6	-0.7	1.9	1.3
Cash and cash equivalents at the end of the period	201.0	303.0	201.0	303.0	262.9

1) Operating profit for January to December 2023 includes the reversal of a EUR 0.6 million provision made for the retroactive payback levy due to the Italian Ministry of Health. See Note 6 on page 16.

Parent Company income statement

SEK million	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jan - Dec 2023
Net sales	11.0	8.6	22.8	16.9	37.7
Cost of goods sold	-0.0	-0.0	-0.1	-0.1	-0.2
Gross profit	11.0	8.6	22.7	16.8	37.5
Other operating income	0.0	0.0	0.0	0.0	0.0
Selling expenses	-	-	-	-0.9	-0.9
Administrative expenses	-5.8	-4.8	-12.1	-9.9	-20.6
Research and development costs	-1.1	-0.3	-2.2	-0.8	-3.1
Other operating expenses	-0.0	-0.0	-0.0	-0.0	-0.0
Operating profit/loss	4.0	3.5	8.4	5.2	12.9
Net interest and similar items	1.4	-0.1	3.5	-0.1	5.2
Profit/loss from financial items	1.4	-0.1	3.5	-0.1	5.2
Profit after financial items	5.4	3.4	11.9	5.2	18.1
Appropriations		-	-	-	-68.4
Profit/loss before tax	5.4	3.4	11.9	5.2	-50.3
Tax ¹	0.1	0.1	0.2	0.2	2.1
Profit/loss for the period	5.5	3.5	12.2	5.3	-48.2
Earnings per share before dilution, SEK	0.34	0.22	0.75	0.33	-2.98
Earnings per share after dilution, SEK	0.32	0.20	0.71	0.31	-2.83
Average no. of shares, before dilution	16,301,895	16,147,748	16,293,182	16,135,576	16,180,907
Average no. of shares, after dilution	17,197,727	17,155,786	17,189,014	17,143,614	17,052,245

As there are no items of other comprehensive income, the Parent Company's earnings are the same as the comprehensive income.

1) See Note 7 on page 16.

Parent Company balance sheet

SEK million	June 30, 2024	June 30, 2023	Dec 31, 2023
ASSETS			
Non-current assets			
Intangible assets			
Capitalized development expenses	53.7	39.7	43.3
Total intangible assets	53.7	39.7	43.3
Financial non-current assets			
Investments in Group companies	69.9	59.4	69.3
Deferred tax assets ¹	20.4	18.3	20.2
Total financial non-current assets	90.3	77.7	89.5
Total non-current assets	144.0	117.3	132.8
Current assets			
Trade receivables	-	20.7	-
Amounts owed by Group companies	110.5	39.5	30.4
Current tax assets	0.8	0.4	0.5
Other receivables	0.3	0.2	0.3
Prepaid expenses and accrued income	3.9	1.2	0.8
Cash in hand and at bank	153.3	261.6	218.6
Total current assets	268.7	323.6	250.5
TOTAL ASSETS	412.7	441.0	383.3
EQUITY AND LIABILITIES			
EQUITY			
Share capital	0.9	0.9	0.9
Statutory reserve	3.7	3.7	3.7
Reserve for development expenses	53.7	39.7	43.3
Total restricted equity	58.4	44.3	48.0
Share premium reserve	526.6	503.2	507.8
Retained earnings	-190.7	-128.0	-131.2
Profit/loss for the period	12.2	5.3	-48.2
Total non-restricted equity	348.1	380.5	328.4
TOTAL EQUITY	406.4	424.9	376.3
LIABILITIES			
Non-current liabilities			
Provisions	1.2	0.9	1.0
Total non-current liabilities	1.2	0.9	1.0
Current liabilities			
Trade payables	0.5	11.7	0.9
Amounts owed to Group companies	0.0	-	0.0
Other liabilities	1.8	1.3	2.1
Accrued expenses and deferred income	2.7	2.2	2.9
Total current liabilities	5.0	15.2	5.9
TOTAL EQUITY AND LIABILITIES	412.7	441.0	383.3

1) See Note 7 on page 16.

DEVYSER DIAGNOSTICS (PUBL)

Changes in the Parent Company's equity

SEK million	Share capital	Non- registered share capital	Reserve for development expenses	Reserves	Share premium reserve	Retained earnings	Profit/loss for the period	Total equity
Opening equity, Jan 1, 2023	0.9	-	30.0	3.7	501.8	-69.2	-49.6	417.7
Profit/loss for the period	-	-	-	-	-	-	5.3	5.3
Appropriation of earnings	-	-	-	-	-	-49.6	49.6	-
Capitalization of development expenses	-	-	9.7	-	-	-9.7	-	-
New share issues ¹	0.0	-	-	-	1.4	-0.1	-	1.3
Employee stock options	-	-	-	-	-	0.6	-	0.6
Warrants	-	-	-	-	-	-0.0	-	-0.0
Closing equity, June 30, 2023	0.9	-	39.7	3.7	503.2	-128.0	5.3	424.9
Profit/loss for the period	-	-	-	-	-	-	-53.5	-53.5
Capitalization of development expenses	-	-	3.6	-	-	-3.6	-	-
New share issues	0.0	-	-	-	4.6	-0.3	-	4.3
Employee stock options	-	-	-	-	-	0.8	-	0.8
Closing equity, Dec 31, 2023	0.9	-	43.3	3.7	507.8	-131.2	-48.2	376.3
Opening equity, Jan 1, 2024	0.9	-	43.3	3.7	507.8	-131.2	-48.2	376.3
Profit/loss for the period	-	-	-	-	-	-	12.2	12.2
Appropriation of earnings	-	-	-	-	-	-48.2	48.2	-
Capitalization of development expenses	-	-	10.4	-	-	-10.4	-	-
New share issues	0.0	0.0	-	-	19.0	-1.6	-	17.4
New share issue expenses	-	-	-	-	-0.2	-	-	-0.2
Employee stock options	-	-	-	-	-	0.8	-	0.8
Warrants	-	-	-	-	-	-0.0	-	-0.0
Closing equity, Jun 30, 2024	0.9	0.0	53.7	3.7	526.6	-190.7	12.2	406.4

Parent Company cash flow

SEK million	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jan - De 2023
Cash flow from operating activities					
Operating profit/loss	4.0	3.5	8.4	5.2	12.9
Adjustments for non-cash items	4.0	5.5	0.4	5.2	12.
- Depreciation, amortization and impairment	1.1	0.3	2.2	0.8	3.
- Other non-cash items	0.5	0.0	1.4	0.1	0.
Interest received	0.0	-0.0	0.0	-	4.
Interest paid	-	-	-	-	-0.
Tax paid	-0.1	-	-0.3	-	
Cash flow from operating activities before changes in working					
capital	5.5	3.8	11.7	6.2	21.
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in operating receivables	-4.8	-2.5	-17.2	-8.3	-16.
Increase (+)/Decrease (-) in operating payables	-7.0	-6.3	-0.9	-0.2	-6
Cash flow from operating activities	-6.3	-5.1	-6.3	-2.3	-1.
Cash flow from investing activities					
Shareholder contributions	-	0.0	-	-	-9.
Investments in intangible non-current assets	-6.5	-7.3	-12.6	-10.5	-16.
Increase/decrease in financial non-current assets	-17.0	-23.0	-63.5	-51.0	-83.
Cash flow from investing activities	-23.5	-30.3	-76.1	-61.5	-109
Cash flow from financing activities					
New share issues	16.6	0.7	17.4	1.3	5
New share issue expenses	-0.2	0.7	-0.2	1.5	5
Stock option plans	-0.2	-0.0	-0.2	-0.0	-0
Cash flow from financing activities	16.4	-0.0 0.7	-0.0 17.1	-0.0 1.3	-0.
	10.4	0.7	17.1	1.5	J.
Cash flow for the period	-13.5	-34.7	-65.3	-62.5	-105
Cash and cash equivalents at the beginning of the period	166.7	296.2	218.6	324.1	324
Cash and cash equivalents at the end of the period	153.3	261.6	153.3	261.6	218

Notes

Note 1 Accounting policies

The interim report for the Devyser Group has been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU. The Swedish Annual Accounts Act and RFR 1, Supplementary Accounting Rules for Groups, have also been applied.

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company applies the Swedish Annual Accounts Act and RFR 2, Accounting for Legal Entities. Under RFR 2, the Parent Company is required to apply the same accounting policies as the Group, which means that IFRS should be applied as far as possible within the framework of the Swedish Annual Accounts Act, the Swedish Pension Obligations Protection Act and tax considerations.

New or amended IFRS standards and other IFRIC interpretations came into effect on January 1, 2024. None of the new standards had any impact on the Group's or Parent Company's financial statements at June 30, 2024.

All amounts are reported in millions of kronor (SEK million) unless otherwise stated. Figures in brackets refer to the previous year. The figures in tables and calculations may be rounded, meaning that the total amounts shown may not always be the exact sum of the rounded amounts.

For more information about the accounting policies, refer to the 2023 Annual Report.

Segment reporting

Devyser applies IFRS 8 Operating segments. Devyser's activities are currently focused on development and sales within a niche and uniform category of goods of a similar nature in the product area of diagnostic reagents, and only one segment is therefore reported, which is fully reflected in the Group's financial statements. All development activities are focused on the same common base product. The Group's strategic steering committee and highest decision-makers, consisting of the CEO and a number of other senior executives who together form the senior management, evaluate the Group's activities as a whole based on products and product development. Sales are monitored by geographic region, currently Europe, the Middle East and Africa (EMEA), Asia-Pacific, North and South America and other regions. Refer to the table on page 5.

Note 2 Incentive programs

Devyser has five outstanding incentive programs for employees and key personnel.

2021/2024 warrant program

The total program comprises 198,000 warrants. The warrants were acquired at market value. Each warrant entitles its holder to subscribe for one new share at SEK 87.06 per share until June 2024. The warrants are vested at a rate of one-third annually, provided that the holder remains an employee.

A total of 20,950 warrants had been granted and were under registration with the Swedish Companies Registration Office as of June 30, 2024. After registration, the program was ended.

2021/2026 employee stock option plan

The total plan comprises 102,000 employee stock options, plus 32,048 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 87.06 per share until June 2026. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2024, a total of 72,700 options had been granted and not exercised. No members of the senior management hold any employee stock options under the plan.

2022/2026 employee stock option plan

The total plan comprises 250,000 employee stock options, plus 78,550 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 89.34 per share until June 2026. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2024, a total of 199,832 options had been granted and not exercised. Two members of the senior management together hold a total of 100,000 employee stock options.

2023/2027 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 101.71 per share until June 2027. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2024, a total of 193,183 options had been granted and not exercised. Fredrik Alpsten, CEO, holds 50,000 options. Five members of the senior management together hold a total of 93,333 employee stock options.

2024/2028 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 135.60 per share until June 2028. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 2024, no options had been granted and not exercised.

Note 3 Related-party transactions

Related-party transactions arise in the normal course of business and are carried out at arm's length and market prices. No transactions with related parties took place during the period other than customary transactions between Group companies and the remuneration of management and the Board.

See Note 2 on incentive programs.

Note 4 Financial assets and liabilities

The financial assets and liabilities on the balance sheet, mainly trade receivables and payables, are measured at amortized cost, which is considered the best estimate of their fair value. Provisions are measured at fair value. There are no derivative instruments.

Notes, continued

Note 5 Revenue from contracts with customers

Devyser applies IFRS 15 Revenue from contracts with customers. The majority of Devyser's revenue is from the sale of goods that are sold primarily to clinical labs at hospitals and other operators. Devyser's performance obligations in its contracts consist of providing the goods specified in them. The performance obligations are met and the revenue is reported when control of the products is transferred to the customer. For most delivery contracts, control is transferred when the goods leave Devyser and the customer can therefore control their use and benefit from them. Billing normally takes place in connection with delivery and is reported at a given point in time. Devyser has chosen to apply the practical solution available under IFRS 15 of not disclosing residual performance obligations if the term is less than one year.

Note 6 Provision due to retroactive payback levy

In 2022, the Italian Ministry of Health introduced a retroactive levy, known as a payback levy, on companies that marketed medical devices in Italy, for sales to the National Health Service (NHS-SSN) from 2015 to 2018.

The total amount provided for amounted to EUR 0.6 million (SEK 6.4 million) as of December 31, 2022, and is reported in the consolidated statement of income and other comprehensive income in Selling expenses, and in the consolidated statement of financial position in Other liabilities. Estimated costs for the years 2019 to 2022 are included. After an evaluation, together with the company's Italian lawyer, of the legal position as it was considered to be, it was judged that the payback levy would not need to be paid. During the second quarter of 2023, EUR 0.2 million (SEK 2.1 million) of the provision were reversed, and during the fourth quarter the remaining EUR 0.4 million (SEK 4.8 million) of the provision were reversed.

Note 7 Deferred tax

Within the Group, deferred tax is mainly recognized for accumulated losses, leases and endowment policies for which there are temporary differences.

The tax effects of loss carryforwards are taken into account only to the extent that there are convincing factors that suggest that these may be utilized in the foreseeable future. There are no time limits on any of the losses.

At year-end 2023, the Parent Company had carry forwards of unused tax losses of SEK 185.8 million (136.9), corresponding to deferred tax assets of SEK 38.3 million (28.2). After valuation, SEK 19.1 million are recognized in deferred tax assets in the balance sheet as of December 31, 2023.

Use of non-IFRS performance measures

The Devyser Group prepares its consolidated financial statements in accordance with IFRS. Only a few performance measures are defined in the IFRS standards. Devyser applies the Guidelines on Alternative Performance Measures (APMs) issued by the European Securities and Markets Authority (ESMA). To support the assessment of the Group's performance made by senior management and other stakeholders, Devyser uses some non-IFRS performance measures. Senior management believes that these measures make it easier to evaluate the performance of the Group.

Definitions of non-IFRS performance measures that are not provided elsewhere in this report are presented in the following table. The measures have been calculated using the actual financial statements, including IFRS 16.

	Apr - Jun 2024	Apr - Jun 2023	Jan - Jun 2024	Jan - Jun 2023	Jan - Dec 2023
Gross margin (gross profit/net sales)					
Gross profit, SEK million	41.4	31.5	83.3	65.1	144.7
Net sales, SEK million	53.2	37.7	104.0	77.2	169.3
Gross margin, %	77.7	83.4	80.1	84.3	85.5
EBITDA margin (EBITDA/net sales)					
Operating profit/loss, SEK million	-23.1	-13.5	-35.3	-32.6	-58.9
Depreciation/amortization, SEK million	-6.8	-2.4	-13.4	-5.1	-13.1
Net sales, SEK million	53.2	37.7	104.0	77.2	169.3
EBITDA margin, %	Neg	Neg	Neg	Neg	Neg
Operating margin (operating profit/net sales)					
Operating profit/loss, SEK million	-23.1	-13.5	-35.3	-32.6	-58.9
Net sales, SEK million	53.2	37.7	104.0	77.2	169.3
Operating margin, %	Neg	Neg	Neg	Neg	Neg
Return on equity (profit for the period/average equity)					
Profit/loss for the period, SEK million	-22.9	-14.6	-35.1	-34.5	-53.6
Average equity, SEK million	371.2	406.6	376.5	415.9	408.3
Return on equity, %	Neg	Neg	Neg	Neg	Neg
Net cash/Net debt (interest-bearing liabilities - interest-bearing assets)					
Interest-bearing liabilities, SEK million	64.8	73.4	64.8	73.4	74.8
Interest-bearing assets, SEK million	201.0	303.0	201.0	303.0	262.9
Net cash (-)/Net debt (+), SEK million	-136.1	-229.6	-136.1	-229.6	-188.2
Equity ratio (closing equity for the period/closing total assets for the period)					
Closing equity, SEK million	367.9	400.3	367.9	400.3	385.1
Closing total assets, SEK million	489.8	527.1	489.8	527.1	510.1
Equity ratio, %	75.1	75.9	75.1	75.9	75.5
Growth adjusted for exchange rate changes (((sales in currency for the period * (previous period's exchange rate - average exchange rate for the period in currency) + net sales)) - previous period's net sales)))/previous period's net sales)					
Net sales in EUR million	3.5	2.6	7.0	5.6	11.7
Net sales in USD million	0.8	0.4	1.4	0.6	1.8
Net sales in GBP million	0.2	0.1	0.2	0.2	0.5
Net sales, SEK million	53.2	37.7	104.0	77.2	169.3
Average exchange rate EUR/SEK	11.5123	11.4609	11.4149	11.3220	11.4751
Average exchange rate USD/SEK	10.7005	10.5194	10.5695	10.4715	10.6121
Average exchange rate GBP/SEK	13.4903	13.1807	13.3566	12.9153	13.1954
Sales growth adjusted for exchange rate changes, %	40.1	12.6	33.5	17.3	24.9

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the fields of inherited diseases, oncology and transplantation. They provide the opportunity to tailor cancer treatments, diagnose a wide range of genetic diseases and follow up transplant patients. Devyser's products, and unique, patented solution, which requires only a single test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of Devyser's business model, and is a prerequisite for long-term value creation over time.

Devyser was founded in 2004 and is based in Stockholm, Sweden. The company has eight in-house sales offices in Europe and the US, as well as a CLIA laboratory in Atlanta, Georgia. In August 2022, Devyser's quality management system was IVDR certified. Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR).

For more information, visit www.devyser.com.

The company's Certified Adviser is Redeye AB.

Contact

Sabina Berlin CFO Tel: +46 739 519 502 Email: sabina.berlin@devyser.com

All reports are published on the company's website: https://investors.devyser.com/en/reports-presentations

Financial calendar

May 8, 2024
May 14, 2024
July 23, 2024
October 30, 2024
February 13, 2025

Devyser Diagnostics AB Instrumentvägen 19 126 53 Hägersten, Sweden www.devyser.com